NRX Pharmaceuticals (NRXP) Change in Account Payables (2020 - 2026)
NRX Pharmaceuticals (NRXP) posted quarterly Change in Account Payables of $129000.0 for Q1 2026, down 27.53% year-over-year from $178000.0 in Q1 2025, and up 892.31% quarter-over-quarter from $13000.0 in Q4 2025.
NRX Pharmaceuticals (NRXP) Change in Account Payables (2020 - 2026) Analysis & Trends
NRX Pharmaceuticals (NRXP) has reported Change in Account Payables for 7 consecutive years, with $129000.0 the latest figure, recorded in Q1 2026.
- In Q1 2026, Change in Account Payables fell 27.53% year-over-year to $129000.0; the TTM figure through Mar 2026 stood at $64000.0 (up 100.9% YoY), while the FY2025 annual figure was $113000.0, up 102.17% from the prior year.
- Change in Account Payables rose to $129000.0 in Q1 2026 per NRXP's latest filing, from $13000.0 in the prior quarter.
- Across five years, Change in Account Payables topped out at $2.1 million in Q2 2024 and bottomed at -$10.2 million in Q4 2024.
- Historically, Change in Account Payables has averaged -$231235.3 across 5 years, with a median of $178000.0 in 2025.
- Annual changes were most pronounced in 2023 — Change in Account Payables surged 1188.04% — and 2024, when it plunged 1115.58%.
- NRX Pharmaceuticals' Change in Account Payables stood at -$92000.0 in 2022, then soared by 1188.04% to $1.0 million in 2023, then slumped by 1115.58% to -$10.2 million in 2024, then jumped by 100.13% to $13000.0 in 2025, then surged by 892.31% to $129000.0 in 2026.
- Business Quant data shows NRXP's Change in Account Payables at $129000.0 in Q1 2026, $13000.0 in Q4 2025, and $601000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Account Payables (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | -66.70 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -8.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 37.53 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | - |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | - |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | - |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | NRX Pharmaceuticals | 132.53 Mn | 105.83 Mn | 426,000.00 | -1.25 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 129,000.00 |
| Mar 31, 2026 | 129,000.00 |
| Dec 31, 2025 | 13,000.00 |
| Dec 31, 2025 | 13,000.00 |
| Sep 30, 2025 | 601,000.00 |
| Sep 30, 2025 | 601,000.00 |
| Jun 30, 2025 | -679,000.00 |
| Jun 30, 2025 | -679,000.00 |
| Mar 31, 2025 | 178,000.00 |
| Mar 31, 2025 | 178,000.00 |
| Dec 31, 2024 | -10.17 Mn |
| Dec 31, 2024 | -10.17 Mn |
| Sep 30, 2024 | 740,000.00 |
| Sep 30, 2024 | 740,000.00 |
| Jun 30, 2024 | 2.12 Mn |
| Jun 30, 2024 | 2.12 Mn |
| Mar 31, 2024 | 2.09 Mn |
| Mar 31, 2024 | 2.09 Mn |
| Dec 31, 2023 | 1.00 Mn |
| Dec 31, 2023 | 1.00 Mn |